| According to foreign media, Queensland-based medical technology company Admedus announced new progress in its patented transcatheter aortic valve replacement (TAVR) program. The company has completed animal testing and successfully completed its unique 3D printed monolithic film for the first time. The aortic heart valve is implanted in the sheep.  △Admedus successfully tested its 3D printed heart valve device Admedus collaborated with a leading European reference laboratory to conduct a 'Admedus Valve Evaluation - A Sheep Model for Aortic Valve Replacement' study, which used sheep to test the safety and feasibility of Admedus' unique 3D printed single-piece molded valve . TAVI represents transcatheter aortic valve replacement, a minimally invasive procedure that assists in the repair of a damaged aortic valve. The TAVR method provides a fully collapsible replacement valve through the catheter to the valve site without the need for open heart surgery.  Admedus' unique 3D printed heart valve provides greater precision and placement mechanisms, allowing surgeons to achieve better fit and reduce the risk of leakage around the valve. In the company's laboratory tests, multiple 3D heart valves used up to 400 million cycles (approximately 10 years for human use). Admedus heart valves remain functional after 400 million cycles, but competitors' heart valves are at 250 million Significant fatigue during the second cycle. The first heart valve that was officially implanted recently officially marks the beginning of the trial period and is expected to last for about five months. It will involve multiple animals and then expand to larger animals to test heart valves. 'When we move on to the next stage of development, today is an important step in the TAVR project,' said Admedus CEO Wayne Paterson, 'excitingly, for the first time, we placed a unique monolithic heart valve in a living In the heart. These experiments are being carried out by global leaders in the field, and we are accelerating the commercialization of products.' The company has previously submitted a patent application for a unique 3D printed single-piece heart valve using its novel ADAPT tissue technology. Invented by Professor Leon Neethling, ADAPT tissue technology is used to make durable, biocompatible for soft tissue repair. Bracket. By utilizing ADAPT technology, Admedus will provide the first and only TAVR with proven resistance to calcification and superior biomechanical control. This revolutionary combination of advantages provides a strong scientific basis for Admedus TAVR. Provide predictable and improved results. Demand for TAVR equipment is growing rapidly - current market value is estimated at $3.5 billion and is expected to increase to $5 billion by 2020. 'The device is expected to be a changer in patients, companies and the TAVR market,' Mr. Patterson Add. Admedus currently has several patent applications related to its TAVR equipment in the United States. |
